Structured around development the next generation of POC molecular diagnostics for syndromic infectious diseases, theTorus Biosystems - designated the Synestia⢠System - is based on the novel integration of qPCR and microarray technologies that enables rapid detection and quantification of DNA (c.30 minutes). Faster and more accurate than conventional methods, the syndromic testing approach delivers rapid, comprehensive, sample-to-answer solutions at the patient point of care in a compact and portable system that supports decentralized healthcare settings. Spun out of the Wyss Institute for Biologically Inspired Engineering at Harvard University, Torus Biosystems is developing to commercializing condition the proprietary DNA/RNA detection technology developed by Wyss Core Faculty member, Peng Yin, PhD, Professor, Department of Systems Biology, Harvard Medical School, and Wyss Alumnus David Zhang, PhD, Associate Professor of Bioengineering, Rice University
